ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2805

Juvenile-Onset Ankylosing Spondylitis Has a Lower Rate of Radiographic Progression Than Adult-Onset Ankylosing Spondylitis

Anthony So1, Ammepa Anton2, Florence Tsui3, Ismail Sari4, Renise Ayearst5, Robert D Inman6 and Nigil Haroon4, 1University of British Columbia, Vancouver, BC, Canada, 2University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, 5Medicine, University Health Network, Toronto, ON, Canada, 6Department of Immunology, University of Toronto, Toronto, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Clinical, juvenile spondylarthropathy, radiography and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Session Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: There are no large radiographic follow up studies assessing progression in juvenile-onset Ankylosing Spondylitis (JoAS) as compared to adult-onset Ankylosing Spondylitis (AoAS). The purpose of this study is to examine the clinical and imaging aspects of JoAS in a large spondylitis clinic.

Methods: The spondylitis clinic has a database of around 1300 patients with confirmed ankylosing spondylitis (AS) as defined by the modified New York criteria. AS patients with symptom onset of back pain at 16 years of age or under were classified as JoAS. They were then matched by gender and duration of back pain to patients with symptom onset of back pain over 16 years old, defined as AoAS, in a 1:2 ratio. Clinical and radiographic data were then extracted. The analysis utilized linear or logistic regression analysis to correct for disease duration, gender, prior anti-TNF exposure, ESR, and HLA-B27 status as appropriate.

Results: 158 JoAS patients were identified and matched to 316 AoAS patients. There was a total of 365 males and 106 females. Baseline mean BASDAI was 4.36 for JoAS and 5.00 for AoAS and was not significantly different when adjusted for prior anti-TNF use. However, patient global disease activity was 4.38 for JoAS and 5.16 for AoAS, which was significantly different (p=0.032) after adjusting for prior anti-TNF use. Current and previous history of smoking exposure, iritis, and psoriasis did not differ between JoAS and AoAS. There was more associated Crohn’s disease in JoAS (13%) versus AoAS (4%), p=0.001. There was no difference in B27 status between the two groups. Baseline mSASSS was lower in JoAS (3.9%) vs AoAS (11.6%), and was statistically different when corrected for prior anti-TNF, duration of back pain, gender, baseline ESR, and B27 status (p<0.001). When followed over time, progression of 1 mSASSS unit or more yearly was lower in the JoAS (11%) vs AoAS (24%), and was still significant when corrected for gender, prior anti-TNF use, ESR, and HLA-B27 status, p=0.018. Progression of 4 mSASSS units or more over any time period was lower in the JoAS (14%) vs AoAS (35%), and was still significant when corrected for the covariates above, p=0.001. More JoAS (65%) were on biologics compared to AoAS (47%), p<0.001. Of the patients on biologics, more JoAS (52%) had switched biologics compared to AoAS (33%), p=0.006.

Conclusion: The rate of axial radiographic progression over time was lower in the JoAS cohort when corrected for covariates. JoAS patients were also on more biologics and switched biologics more regularly compared to AoAS patients.


Disclosure: A. So, None; A. Anton, None; F. Tsui, None; I. Sari, None; R. Ayearst, None; R. D. Inman, None; N. Haroon, Abbvie, Amgen, Janssen, Novartis, 5.

To cite this abstract in AMA style:

So A, Anton A, Tsui F, Sari I, Ayearst R, Inman RD, Haroon N. Juvenile-Onset Ankylosing Spondylitis Has a Lower Rate of Radiographic Progression Than Adult-Onset Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/juvenile-onset-ankylosing-spondylitis-has-a-lower-rate-of-radiographic-progression-than-adult-onset-ankylosing-spondylitis/. Accessed March 23, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/juvenile-onset-ankylosing-spondylitis-has-a-lower-rate-of-radiographic-progression-than-adult-onset-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences